TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQTM (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development.

Company profile
Ticker
TGTX
Exchange
Website
CEO
Michael Weiss
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ATLANTIC PHARMACEUTICALS INC, ATLANTIC TECHNOLOGY VENTURES INC, MANHATTAN PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Ariston Pharmaceuticals, Inc. • TG Biologics, Inc. • TG Therapeutics AUS Pty Ltd ...
IRS number
363898269
TGTX stock data
News

Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
9 Aug 22
Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day Session
8 Aug 22
TG Therapeutics Q2 EPS $(0.30) Up From $(0.59) YoY
8 Aug 22
12 Health Care Stocks Moving In Tuesday's After-Market Session
2 Aug 22
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
27 Jun 22
Press releases
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - TGTX
12 Aug 22
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of U, MOLN and TGTX
12 Aug 22
TGTX CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages TG Therapeutics (TGTX) Investors with Losses to Contact Firm's Attorneys, Securities Fraud Class Action Pending
12 Aug 22
SHAREHOLDER ALERT: TGTX YQ WEBR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
12 Aug 22
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in TG Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
12 Aug 22
Analyst ratings and price targets
Current price
Average target
$11.00
Low target
$5.00
High target
$17.00
B. Riley Securities
Maintains
$17.00
B of A Securities
Initiated
$5.00
Investment data
Securities sold
Number of investors
Calendar
10 May 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 186.94M | 186.94M | 186.94M | 186.94M | 186.94M | 186.94M |
Cash burn (monthly) | 37.74M | 23.82M | 22.29M | 26.87M | 22.9M | 23.58M |
Cash used (since last report) | 166.84M | 105.31M | 98.55M | 118.79M | 101.23M | 104.25M |
Cash remaining | 20.11M | 81.63M | 88.39M | 68.15M | 85.71M | 82.69M |
Runway (months of cash) | 0.5 | 3.4 | 4.0 | 2.5 | 3.7 | 3.5 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Jul 22 | Charney Laurence N | Common Stock | Grant | Acquire A | No | No | 0 | 43,732 | 0 | 264,729 |
20 Jul 22 | Echelard Yann | Common Stock | Grant | Acquire A | No | No | 0 | 43,732 | 0 | 192,848 |
20 Jul 22 | Sagar Lonial | Common Stock | Grant | Acquire A | No | No | 0 | 43,732 | 0 | 128,732 |
20 Jul 22 | Daniel Hume | Common Stock | Grant | Acquire A | No | No | 0 | 43,732 | 0 | 198,239 |
20 Jul 22 | Kenneth Hoberman | Common Stock | Grant | Acquire A | No | No | 0 | 43,732 | 0 | 222,685 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 185 |
Opened positions | 33 |
Closed positions | 45 |
Increased positions | 73 |
Reduced positions | 46 |
13F shares | Current |
---|---|
Total value | 1.05B |
Total shares | 102.63M |
Total puts | 1.51M |
Total calls | 2.09M |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
FMR | 20.33M | $193.33M |
Vanguard | 12.13M | $115.37M |
STT State Street | 9.63M | $91.57M |
BLK Blackrock | 8.94M | $84.98M |
Maverick Capital | 6.68M | $63.51M |
Wellington Management | 4.02M | $38.24M |
LFB Biotechnologies S.A.S.U. | 2.61M | $36.48M |
683 Capital Management | 2.6M | $24.72M |
Geode Capital Management | 2.19M | $20.81M |
Millennium Management | 2.18M | $20.7M |
Financial report summary
?Competition
Bristol-Myers Squibb • Celgene • Astrazeneca • Roche • Viracta Therapeutics • Curis • Novartis • Oncternal Therapeutics • Stemline Therapeutics • GenmabManagement Discussion
- Product revenue, net. Product revenue, net for the three months ended March 31, 2022 was $2.0 million compared to $0.8 million for the three months ended March 31, 2021. Product revenue, net consisted of net product sales of UKONIQ in the United States. In February 2021, we began commercial sales of UKONIQ within the U.S. following FDA approval. The $1.2 million increase was primarily driven by an increase in product shipments for UKONIQ as a result of greater market penetration. The increase in product shipments is partially offset by the recording of an additional allowance for sales returns in the first quarter of 2022 due to the anticipated increase in returns resulting from the voluntary withdrawal of UKONIQ from the U.S. market announced on April 15, 2022. Any product sales subsequent to the voluntary withdrawal are limited to existing patients that elect to remain on treatment and no shipments for new prescriptions are allowed. Therefore, it is expected product revenue, net will decline significantly throughout 2022 as a result of the voluntary market withdrawal of UKONIQ.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Good
|
New words:
addtion, amplifying, anniversary, anti, ASC, Canada, canceled, Carolina, Chairman, check, convened, death, dismantle, driven, electronic, epitope, extinguishment, fashion, foreseen, France, gather, geopolitical, Georgia, Germany, glycoengineered, hoc, host, HR, imbalance, immunology, Interbank, invaded, invasion, Lender, military, NC, neighboring, North, notified, ODAC, OS, outdated, overarching, partake, path, paused, penalty, penetration, Poland, prompt, refinance, reinstated, reset, retention, retirement, Russia, Russian, Samsung, Slovakia, streamlining, SWIFT, Ukraine, undermining, unrestricted, vi, Vice, west, withdrawn, withdrew
Removed:
AbbVie, acalabrutinib, account, accrue, achieved, adjustment, administer, advancing, AEs, AKS, allocated, allocating, ALT, analyst, annum, antigen, ASH, AST, AstraZeneca, ASU, authoritative, axicabtagene, Bayer, begin, bispecific, Brexit, BTK, budgetary, build, buying, calculate, calculating, capitalized, casein, channel, Checkpoint, chimeric, ciloleucel, closely, CMO, cohort, collectability, comprising, computation, Concurrently, consist, constraint, copanlisib, core, Cornell, CR, customary, damaged, delta, dependence, depict, deplete, depression, detected, display, distancing, DLBCL, drastically, duvelisib, earned, ending, enhancement, epidemic, Epizyme, epsilon, error, evolved, exacerbated, exceed, expired, explicitly, exploratory, explore, extranodal, FASB, feasible, filer, focusing, forecasted, formally, frame, Furman, generation, generically, Gilead, globe, goodwill, Gribben, hedging, heightening, hematological, Hematology, Hengrui, ibrutinib, idelalisib, immunotherapy, impairment, inclusion, inclusive, indexed, instability, integrated, interaction, interactive, intraperiod, Janssen, Japan, Jiangsu, John, language, launched, left, lenalidomide, lien, macroeconomic, MCL, Medicine, multicenter, NaN, NCCN, nodal, Novimmune, ocrelizumab, ODD, ofatumumab, opportunistic, optimal, ORR, owe, paydown, performing, persist, pharmacologic, pharmacy, phosphoinositide, prioritized, professional, promised, promote, rash, ratably, realizable, receptor, recession, recognize, recognizing, reflect, regularly, remained, remote, remotely, requesting, requirement, resume, returned, reversal, Richard, rituximab, robust, Roche, satisfied, scalable, Senate, settled, shipment, Simplifying, slowdown, specialty, splenic, spreading, Squibb, step, suitable, sum, supported, surge, targeting, tazemetostat, timeline, today, Topic, tranche, Tricare, triple, Tyrosine, underinsured, unexpectedly, uninsured, unit, variant, venetoclax, Verastem, vesting, virtual, virtually, Weill, worked, workforce, Wuhan
Financial reports
Current reports
8-K
TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
8 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
23 Jun 22
8-K
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
18 Apr 22
8-K
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
1 Mar 22
8-K
Other Events
27 Jan 22
8-K
Entry into a Material Definitive Agreement
4 Jan 22
8-K
TG Therapeutics Provides Regulatory Update
30 Nov 21
8-K
TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
4 Nov 21
8-K
TG Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
2 Aug 21
8-K
Departure of Directors or Certain Officers
22 Jun 21
Registration and prospectus
S-8
Registration of securities for employees
24 Jun 22
424B5
Prospectus supplement for primary offering
16 Dec 20
424B5
Prospectus supplement for primary offering
14 Dec 20
424B5
Prospectus supplement for primary offering
9 Nov 20
424B5
Prospectus supplement for primary offering
18 May 20
424B5
Prospectus supplement for primary offering
14 May 20
424B5
Prospectus supplement for primary offering
20 Mar 20
424B5
Prospectus supplement for primary offering
23 Dec 19
S-3ASR
Automatic shelf registration
5 Sep 19
RW
Registration withdrawal request
5 Sep 19
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
PRE 14A
Preliminary proxy
20 Apr 21
PX14A6G
Letter to shareholders
29 May 20
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
PX14A6G
Letter to shareholders
31 May 19
DEFA14A
Additional proxy soliciting materials
30 Apr 19
Other
CT ORDER
Confidential treatment order
17 Sep 18
EFFECT
Notice of effectiveness
24 Jul 18
CORRESP
Correspondence with SEC
17 Jul 18
UPLOAD
Letter from SEC
16 Jul 18
CT ORDER
Confidential treatment order
29 Apr 18
EFFECT
Notice of effectiveness
12 Jun 17
CORRESP
Correspondence with SEC
8 Jun 17
CT ORDER
Confidential treatment order
3 Oct 16
CT ORDER
Confidential treatment order
3 Aug 15
CT ORDER
Confidential treatment order
20 Jan 15
Ownership
4
TG THERAPEUTICS / MICHAEL S WEISS ownership change
22 Jul 22
4
TG THERAPEUTICS / Sean A Power ownership change
22 Jul 22
4
TG THERAPEUTICS / Sagar Lonial ownership change
22 Jul 22
4
TG THERAPEUTICS / DANIEL HUME ownership change
22 Jul 22
4
TG THERAPEUTICS / Kenneth Hoberman ownership change
22 Jul 22
4
TG THERAPEUTICS / Yann Echelard ownership change
22 Jul 22
4
TG THERAPEUTICS / Laurence N Charney ownership change
22 Jul 22
SC 13G/A
TG THERAPEUTICS / FMR ownership change
11 Jul 22
SC 13G/A
TG THERAPEUTICS / VANGUARD ownership change
9 Feb 22
SC 13G/A
TG THERAPEUTICS / FMR ownership change
9 Feb 22
Patents
Utility
Triple Combination to Treat B-cell Malignancies
12 May 22
Methods for treating B-cell malignancies are provided comprising administering a triple combination of agents, comprising: (i) a PI3K-delta selective inhibitor (e.g., umbralisib); (ii) an anti-CD20 antibody (e.g., ublituximab); and (iii) the Bruton's tyrosine kinase (BTK) inhibitor TG-1701.
Utility
Combination of ANTI-CD20 Antibody, P13 Kinase-delta Selective Inhibitor, and BTK Inhibitor to Treat B-cell Proliferative Disorders
10 Jun 21
Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor.
Utility
Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders
6 Apr 21
Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor.
Utility
Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor
14 Oct 20
Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorders.
Utility
Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
3 Aug 20
Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorderes.
Transcripts
2022 Q2
Earnings call transcript
8 Aug 22
2021 Q4
Earnings call transcript
1 Mar 22
2021 Q3
Earnings call transcript
5 Nov 21
2021 Q2
Earnings call transcript
2 Aug 21
2021 Q1
Earnings call transcript
10 May 21
2020 Q4
Earnings call transcript
2 Mar 21
2020 Q2
Earnings call transcript
10 Aug 20
2019 Q4
Earnings call transcript
3 Mar 20
2019 Q3
Earnings call transcript
12 Nov 19
2019 Q2
Earnings call transcript
9 Aug 19
Reddit threads
Daily Discussion Thread - August 11, 2022
11 Aug 22
(8/8) Monday's Pre-Market Stock Movers & News
8 Aug 22
Daily Discussion Thread - August 5th, 2022
5 Aug 22
Daily Discussion Thread - August 1st, 2022
1 Aug 22
Daily Discussion Thread - July 29th, 2022
29 Jul 22
What Are Your Moves Tomorrow - July 29, 2022
28 Jul 22
Jan 24 put option exercised early?
24 Jun 22
A Total Twist On The Regular - Stocks You Watch For Failure
14 Jun 22
Daily Discussion Thread - May 9th, 2022
9 May 22
Daily Discussion Thread - May 6th, 2022
6 May 22